Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GMAB) Cash from Operations (2023 - 2025)

Historic Cash from Operations for Genmab A (GMAB) over the last 3 years, with Q4 2025 value amounting to $301.0 million.

  • Genmab A's Cash from Operations fell 2262.21% to $301.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year increase of 532.86%. This contributed to the annual value of $1.2 billion for FY2025, which is 532.86% up from last year.
  • Latest data reveals that Genmab A reported Cash from Operations of $301.0 million as of Q4 2025, which was down 2262.21% from $536.0 million recorded in Q3 2025.
  • Over the past 5 years, Genmab A's Cash from Operations peaked at $536.0 million during Q3 2025, and registered a low of -$4.6 billion during Q4 2023.
  • Over the past 3 years, Genmab A's median Cash from Operations value was $287.0 million (recorded in 2025), while the average stood at -$258.3 million.
  • In the last 5 years, Genmab A's Cash from Operations surged by 10838.9% in 2024 and then plummeted by 7168.95% in 2025.
  • Quarter analysis of 3 years shows Genmab A's Cash from Operations stood at -$4.6 billion in 2023, then soared by 108.39% to $389.0 million in 2024, then fell by 22.62% to $301.0 million in 2025.
  • Its last three reported values are $301.0 million in Q4 2025, $536.0 million for Q3 2025, and $62.0 million during Q2 2025.